Kornimate/medical-research-clean huggingface dataset:
canned herring for prevention of childhood malnutrition during the early rainy season in rural guinea-bissau

Conditions: Malnutrition; Undernutrition

Summary: this study will test the effectiveness of a weekly village distribution of canned herring for prevention of malnutrition in children aged 2-5 years old during a food-insecure time of the year in rural villages in guinea-bissau. the study will use community health workers to conduct the herring distribution, making this a test that will provide valuable information on what could become a practical food aid supplementation practice. the primary study hypothesis is that distribution of canned herring as a weekly food supplement to families with young children at the beginning of the rainy season will prevent a seasonal decrease in weight-for-age z-score (primary variable) of children with mild to moderate malnutrition at baseline.


Eligibility criteria:
inclusion criteria: * village leaders willing to allow the study to take place in their village * village must have community health workers who are willing to do the weekly distribution of herring to enrolled families and are able to keep the necessary records documenting the distribution. * children age 2-5 currently living in a selected village * parents willing to participate in the study exclusion criteria: * there are no eligibility exclusions for this study. * if a child is identified with severe malnutrition at the baseline measurement, the family will be advised to take the child for treatment rather than participate in the study.

Keywords: malnutrition undernutrition z-score guinea-bissau food aid
emdogain implementation with transcrestal sinus lifting and dental implant placement

Conditions: Osseointegration Failure of Dental Implant; Bone Density Increased

Summary: the aim of this study is to evaluate the clinical and radiographic results of implants placed using osteotome sinus ﬂoor elevation (osfe) with and without simultaneous enamel matrix derivative (emd) application.

twenty-four patients will be randomly assigned into two groups: group i: (emd+osfe) (n=20 implants, 13 patients) osfe with emd application, and group ii 8osfe): (n=20 implants, 11 patients) osfe without emd application. the patients will be recall at 3- and 12- months after surgery. the residual bone height (rbh), implant protrusion length (ipl), peri-implant sinus bone level (sbl), endo-sinus bone gain (esbg), implant stability and peri-implant bone density values (hounsfield units) will be assessed.

Eligibility criteria:
inclusion criteria: * partial edentulism in the maxillary posterior region for at least 4 months from tooth loss and require implant treatment * adequate bone thickness for primary stabilization * residual bone height ranged from 4 mm to 6 mm * systemic and local conditions compatible with implant placement and sinus ﬂoor elevation * antagonist teeth exclusion criteria: * uncontrolled diabetes mellitus or other systemic disorders (such as; hepatitis, tuberculosis, aids) * pregnancy * untreated periodontal disease * endodontic lesions or other oral disorders * heavy smokers (≥10 cigarettes per day) * acute or chronic rhinitis * sinusitis or pathology in sinus * inadequate residual bone height and quality to achieve implant stability * previous implant treatment/failure or bone augmentation in the implant site * sinus perforation as confirmed via valsalva maneuver * insufficient primary implant stability measured by rfa

Keywords: enamel matrix derivated maxillary sinus
evaluating ultrasound-guided needle knife for dupuytren's contracture

Conditions: Dupuytren Contracture

Summary: this study aims to evaluate the efficacy and safety of ultrasound-guided needle knife dissection in treating dupuytren's contracture. the procedure is designed to improve hund function and minimize complications associated with the conventional surgical methods.

dupuytren's contracture is a disease mainly characterized by the progressive fibrosis of the palmar fascia with subsequent hand deformity and dysfunction. the current study seeks to explore, through this minimally invasive technique, ultrasound-guided needle knife dissection regarding rom and patient satisfaction. the procedure will be carried out under ultrasound guidance to ensure safety and completeness with the accuracy of precise dissection. primary outcome measures will concern hand mobility, and secondary measures will evaluate patient self-reported satisfaction and any complications for the 6-month follow-up period.

Eligibility criteria:
inclusion criteria: * participants diagnosed with dupuytren's contracture. * willing to undergo ultrasound-guided needle knife dissection exclusion criteria: * patients who have undergone previous surgery or needle apponeurotomy for dupuytren's contracture on the same hand. * active hand infections, open wounds, or dermatological conditions in the treatment area. * coagulopathy or use of anticoagulant that cannot be safely paused * neuromuscular disorders affecting hand function * pregnancy or breastfeeding * uncontrolled systemic illnesses, such as poorly managed diabetes or cardiovascular disease. * known hypersensitivity to local anesthetics.

Keywords: ultrasound-guided procedure dupuytrene's contracture tubiana grade fibrotic cords acupotomy functional hand recovery palmar fascia fibrosis
tamoxifen dose adjustment on indonesian female er+ breast cancer patients based on cyp2d6 genotype and endoxifen levels

Conditions: ER+ Breast Cancer

Summary: the objectives of this study is to perform cyp2d6 genotyping and metabolite concentrations analysis on er+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the cyp2d6 genotypes and endoxifen levels.


Eligibility criteria:
inclusion criteria: * diagnosed with er+ breast cancer * have taken tamoxifen daily for at least 2 months exclusion criteria: * have not taken tamoxifen daily for at least 2 months

Keywords: breast cancer tamoxifen cyp2d6 endoxifen
influence of sacubitril/valsartan on autonomic cardiac nervous system in heart failure patients: an exploratory study

Conditions: Heart Failure Patients

Summary: sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. the compound is also believed to have antiarrhythmic properties as it has been shown to significantly reduce ventricular arrhythmias in patients with implantable cardioverter defibrillators. patients suffering from heart failure with reduced ejection fraction show impaired heart rate variability, knowing that in these patients such impairment is highly associated with an increased risk of sudden cardiac death. in its pivotal study, sacubitril/valsartan demonstrated a significant advantage over enalapril in terms of cardiovascular mortality and rehospitalization. against this background, this study was designed to analyze the largely unknown electrophysiological effects of sacubitril/valsartan on the autonomic cardiac nervous system by determining heart rate variability.


Eligibility criteria:
inclusion criteria: * patients with symptomatic severe heart failure with reduced ejection fraction (lvef ≤40%,) * age \> 20 years * consent capacity * sinus rhythm * suitable for a drug conversion from at1/ace inhibitors to sacubitril/ valsartan exclusion criteria: * age \< 18 years * atrial fibrillation * pregnancy * lack of consent capacity * contraindications for a therapy with sacubitril/ valsartan
a 6-week multicenter trial of varenicline tartrate for cognitive impairment in subjects with schizophrenia

Conditions: Schizophrenia

Summary: the primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg bid and 1mg bid) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic subjects who are receiving treatment with atypical antipsychotic medications. a secondary objective is to evaluate the safety and tolerability of two doses of varenicline in symptomatically stable schizophrenic subjects who are receiving treatment with atypical antipsychotic medications.


Eligibility criteria:
inclusion criteria: * have a current diagnosis of schizophrenia * subjects must be on ongoing maintenance antipsychotic monotherapy or combination therapy with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone. * evidence of stable symptomatology ≥3 months (eg, no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of symptoms of schizophrenia). exclusion criteria: * subjects with a current dsm-iv axis i diagnosis other than schizophrenia. * current treatment with conventional antipsychotics (e.g. fluphenazine, haloperidol) or clozapine, or the use of adjunctive anticholinergic treatment.

Keywords: schizophrenia, treatment, cognition
clevidipine infusion for blood pressure management after successful revascularization in acute ischemic stroke

Conditions: Stroke, Acute; Blood Pressure; Mechanical Thrombectomy

Summary: the clever study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using clevidipine (on-label use) in ais patients undergoing standard of care mechanical thrombectomy (mt) within 24-hours of symptoms onset.

the clever study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using clevidipine (on-label use) in ais patients undergoing standard of care mechanical thrombectomy (mt) within 24-hours of symptoms onset. eligible patients will be randomized 1:1 to a systolic blood pressure goal after successful mt (mtici 2c or greater) of either: 90-120mmhg (intensive bp management group) or 90-160mmhg (standard bp management group). patients enrolled into the study will be followed and assessed for up to 3 months.

Eligibility criteria:
inclusion criteria: * 1. age 18 or older * 2. acute hypertension (systolic blood pressure of greater than 140 mmhg) at recanalization * 3. anterior circulation ischemic stroke symptoms and confirmed occlusion (ica, m1, or m2) on angiogram with mechanical thrombectomy initiated within 24 hours since last known well * 4. success revascularization score of mtici 2c or higher after mechanical thrombectomy * 5. aspects score of greater than 6 * 6. premorbid mrs 0-4 * 7. signed informed consent within 30 minutes from end of mt procedure. exclusion criteria: * 1. presence of any hemorrhage and/or aspect score ≤6 on baseline head ct scan * 2. pregnant or lactating * 3. acute traumatic brain injury * 4. patient on active dialysis * 5. intracranial neoplasm * 6. acute or recent stemi in the last 30 days * 7. severe arrhythmias, unstable cardiac function * 8. any terminal medical condition with life expectancy less than 6 months * 9. concurrent enrollment in another trial that could confound the results of this study
early detection of breast cancer and cervical cancer in women in india

Conditions: Breast Cancer; Cervical Cancer

Summary: rationale: health education programs and screening methods, such as clinical breast examination and examination of the cervix, may help reduce the number of women who develop breast cancer and cervical cancer. purpose: this randomized clinical trial is studying the early detection of breast cancer and cervical cancer in women in india.

objectives: * to investigate the effectiveness of well planned health education programs (hep) and low-cost screening methods (e.g., clinical breast examination \[cbe\] and visual inspection of the cervix painted with 4% acetic acid \[via\]) in down-staging and reducing the incidence of and mortality due to breast and cervical cancer. outline: patients are randomized to 1 of 2 arms. * arm i (intervention): participants undergo intervention comprising health education programs (hep), clinical breast examination (cbe), and visual inspection of the cervix painted with 4% acetic acid (via) every 2 years for up to 8 years. participants also undergo active surveillance over 8 years. * arm ii (control): participants receive one hep. participants also undergo active surveillance over 8 years.

Eligibility criteria:
disease characteristics: * resides in 1 of 20 geographically defined clusters within the slums of mumbai, india patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: breast cancer cervical cancer
safety and efficacy study of viaskin peanut in peanut-allergic young children 1-3 years of age

Conditions: Peanut Allergy

Summary: the study aims to assess the safety and efficacy of viaskin peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by epicutaneous immunotherapy (epit).

the study comprised of two parts: * in part a, subjects were randomized to receive either viaskin peanut 250 mcg, or viaskin peanut 100 mcg or the placebo in a 2:1 ratio, for 12 months. after 3 months of treatment, a data safety monitoring board had to determine the active dose to be applyed during the part b * in part b, subjects were randomized to receive either viaskin peanut 250 mcg or the placebo in a 2:1 ratio, for 12 months

Eligibility criteria:
key inclusion criteria: * male or female from 1-3 years of age; * physician-diagnosed peanut allergy; * peanut-specific ige level \> 0.7 ku/l; * positive peanut spt with a largest wheal diameter ≥ 6 mm; * positive dbpcfc at ≤ 300 mg peanut protein; key exclusion criteria: * uncontrolled asthma; * history of severe anaphylaxis to peanut; * prior immunotherapy to any food or other immunotherapy; * generalized severe dermatologic disease;

Keywords: epit epicutaneous immunotherapy viaskin
d-dimer and ipg for recurrent thrombosis (direct)

Conditions: Deep Vein Thrombosis; Pulmonary Embolism

Summary: to simplify and improve the diagnostic approach to patients with clinically suspected recurrent dvt by determining whether the results of the combination of ipg and d-dimer testing, using a whole blood agglutination assay, can be used in the management of such patients.


Eligibility criteria:
inclusion criteria: * suspected deep vein thrombosis * history of previous dvt or pe exclusion criteria: * comorbid condition limiting survival to less than 6 months * contraindication to contrast medium (allergy, renal dysfunction, creatinine \> 150mcmol/l) * receiving long-term warfarin or heparin therapy * received full-dose heparin therapy for more than 48 hours * pregnancy * symptomatic for pulmonary embolism * absence of symptoms within 5 days of presentation * geographic inaccessibility which precludes follow-up

Keywords: deep vein thrombosis dvt pulmonary embolism pe venous thromboembolism vte d-dimer ipg
the effect of two methods applied to mothers on insufficient milk perception, breastfeeding motivation, fatigue, anxiety

Conditions: Caesarean Section

Summary: although the world health organization predicts the caesarean section rate to be 10-15%, the caesarean section rate in turkey is 52%, more than three times the international standard. it is very important to eliminate the physical and psychosocial problems experienced by women during this period, to encourage breastfeeding, and at the same time to protect and improve maternal health. maintaining the mother's well-being after cesarean section and supporting pharmacological treatment with non-pharmacological practices have an important place in nursing care. therefore, this study will examine the effects of oxytocin massage and reflexology applied to mothers in the post-cesarean period on the perception of insufficient milk, breastfeeding motivation, fatigue, anxiety and uterine involution.


Eligibility criteria:
inclusion criteria: * mothers who gave birth at the age of 18 and over * the one who is married * at least primary school graduate, * primiparous mothers who gave birth by cesarean section, * having a single, healthy newborn at full term, * those who did not experience any problems during pregnancy and the early postpartum period, * the tissue integrity in the area to be applied is complete and healthy, * breastfeeding her baby after birth, * the baby is healthy, has no problems with the sucking reflex and does not have any congenital anomalies, * women who agree to participate in the research will be included in the study. exclusion criteria: * those who gave birth by cesarean section before the 37th week of pregnancy, * women who gave birth by cesarean section with combined anesthesia, * discharged before 36 hours after birth, * having chronic diseases such as heart disease, diabetes, hypertension, * those with infectious diseases, infections, open wounds, masses, fractures, dislocations, deformities, varicose veins, burns, eczema, hematomas, thrombophlebitis, deep vein thrombosis on the foot skin, * experiencing any postpartum complications, * their baby is not with their mother for any reason, * those who have received a psychiatric diagnosis such as anxiety and depression, * women who want to leave the research at any stage of the research

Keywords: reflexology oxytocin massage fatigue anxiety milk production
a study to evaluate bms-986036 in obese adults with type-2 diabetes

Conditions: Diabetes Mellitus Type 2

Summary: the purpose of this study is to assess the potential of bms-986036 for treatment obese adults with type-2 diabetes.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * diagnosed with type-2 diabetes mellitus with hba1c ≥6.5% to less than 10.0% * body mass index 30.0 to 50.0 exclusion criteria: * any significant acute or chronic medical illness * inability to self-administer subcutaneous injections * inability to be venipunctured * evidence of organ dysfunction beyond what is consistent with the target population * history of allergy to pegylated compounds or fibroblast growth factor 21 (fgf21) related compounds
multistem administration for covid-19 induced ards (macovia)

Conditions: ARDS

Summary: multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled phase 2/3 part to evaluate the safety and efficacy of multistem therapy in subjects with moderate to severe acute respiratory distress syndrome (ards) due to pathogens including covid-19.


Eligibility criteria:
inclusion criteria: diagnosis of new acute-onset moderate to severe ards, as defined by the berlin criteria, requiring an endotracheal or tracheal tube, evidence of pneumonia or severe localized or systemic infection exclusion criteria: moribund subject who, in the opinion of the investigator, is not expected to survive at least 48 hours and end-stage severe chronic lung disease

Keywords: covid19 respiratory distress adult stem cells
subcutaneous injection of erythropoietin on visual functions in patients with late onset optic neuropathy

Conditions: Optic Neuropathy

Summary: this study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. this study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Eligibility criteria:
inclusion criteria: * patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases) exclusion criteria: * patients with perforating ocular injuries were excluded.
osteoarthritis structural changes assessed by magnetic resonance imaging and neuropathic pain in knee osteoarthritis

Conditions: Neuropathic Pain; Knee Osteoarthritis

Summary: the primary objective of this study is to identify osteoarthritis (oa) structural changes, as assessed by mri, that best correlate with the presence of neuropathic pain (np) using the paindetect questionnaire (paindetect ≥ 13) on a population of patients with oa of the knee experiencing moderate to severe pain (vas ≥ 40 mm).

this study is a multicentre, cross-sectional observational pilot study. the presence of np was determined based on use of the paindetect questionnaire (score 1 to 38), the score of which was defined for the purpose of the study as ≥ 13. a total of 50 oa patients with moderate to severe pain (vas ≥ 40), 25 without the presence of np (oa/np-) (paindetect score \< 13), and 25 with the presence of np (oa/np+) (paindetect score ≥ 13) were enrolled. since this is a pilot study, we arbitrarily determined the number of patients at 50, which represents 25 patients per arm, a number deemed sufficient to identify the knee oa structural changes that could be preferentially associated with np.

Eligibility criteria:
inclusion criteria: * individuals of either sex, aged 40 years and more; * followed in an ambulatory clinic; * presenting with primary oa of the knee according to american college of rheumatology (acr) criteria; * with an oa of radiological stages 2 and 3 according to kellgren-lawrence; * knee pain for at least 1 month out of the 3 months preceding the study; * visual analog scale (vas) of pain while walking on a flat surface ≥ 40 mm; * agrees to sign the informed consent form; * not taking part in another clinical trial; * agrees to respect the protocol. exclusion criteria: * other bone and articular diseases (antecedents and/or current signs); * presenting with isolated knee lateral compartment oa defined by joint space loss in the lateral compartment only; * knee surgery on the study knee; * comorbidities that restrict knee function; * had received any investigational drug within 30 days or 5 half lives (whichever is greater) prior to entering the study; * unable to give informed consent; * counter-indication to an mri examination; * baseline visit cartilage volume cannot be calculated from the mri due to advanced oa or any other technical reason; * abnormal findings and or any other condition, which, in the investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data through mri to achieve the objectives of the study.

Keywords: neuropathic pain knee osteoarthritis mri
upper extremity rehabilitation training using brain-machine interface biofeedback in stroke patients with hemiplegia

Conditions: Stroke; Hemiplegia

Summary: this is a study to evaluate the efficacy of upper extremity rehabilitation using brain-machine interface (bmi) on individuals with hemiplegia due to stroke. bmi is a device that can record and analyze human brain signals (in this study functional near-infrared spectroscopy was used) and also provide live feedback (by pneumatic glove movement) to the individual wearing it. this device hypothetically enables more accurate training by reinforcing the correctly activated brain signal repeatedly then conventional therapy. in phase 1 study investigators will evaluate the feasibility of bmi on chronic stroke participants. 5 sessions of bmi-assisted occupational therapy (ot) will be performed and the fugl meyer assessment-upper limb (fma-ul) score change between the pre-treatment and post-treatment will be analyzed by paired t-test. in phase 2 study, a randomized controlled study will be performed by randomly allocating participants to either control (ot plus ot) or experimental group (bmi-assisted ot plus ot) and the difference of fma-ul score change between the two groups will be analyzed by student's t-test.


Eligibility criteria:
inclusion criteria: * subcortical stroke with hemiplegia * 1st stroke * time since onset is less than 3 months * brunnstrom stage 2,3 exclusion criteria: * recurred stroke * mmse score below 10 * delirium * unstable medical condition * pregnancy * cannot sustain sitting position for 30 minutes * pain that limits upper extremity exercise

Keywords: neural plasticity brain machine interface functional near-infrared spectroscopy stroke upper extremity function recovery